Literature DB >> 18006337

Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events.

R J Haier1, K Head, E Head, I T Lott.   

Abstract

BACKGROUND: We report functional and structural brain indicators that may precede the onset of dementia in individuals with Down's syndrome (DS).
METHODS: Middle-aged adults with DS (n=19), a group known to be at high risk for dementia, were studied with (1) positron emission tomography (PET) to determine cerebral glucose metabolic rate (GMR), (2) structural magnetic resonance imaging (MRI) to determine gray matter volume (GM), and (3) ratings of potential dementia indicators based on a structured interview of caregiver observations designed to evaluate individuals with low intelligence.
RESULTS: Although none of the participants showed clinical signs of dementia, ratings of dementia indicators were correlated to both functional and structural imaging. The strongest correlations (p<.05, corrected for multiple comparisons) included the combination of higher GMR and decreased GM volume in parts of the temporal cortex, including the parahippocampus/hippocampus, in the thalamus, caudate, and frontal lobe (BA 47).
INTERPRETATION: The combination of increased GMR overlapping with less gray matter in these areas may be consistent with a compensatory brain response to an early stage of the disease process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006337      PMCID: PMC2409285          DOI: 10.1016/j.neuroimage.2007.09.064

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  66 in total

1.  A voxel-based morphometric study of nondemented adults with Down Syndrome.

Authors:  Nathan S White; Michael T Alkire; Richard J Haier
Journal:  Neuroimage       Date:  2003-09       Impact factor: 6.556

2.  A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry.

Authors:  G B Karas; E J Burton; S A R B Rombouts; R A van Schijndel; J T O'Brien; P h Scheltens; I G McKeith; D Williams; C Ballard; F Barkhof
Journal:  Neuroimage       Date:  2003-04       Impact factor: 6.556

3.  Diagnosis of dementia in individuals with intellectual disability.

Authors:  E H Aylward; D B Burt; L U Thorpe; F Lai; A Dalton
Journal:  J Intellect Disabil Res       Date:  1997-04

4.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.

Authors:  S Minoshima; B Giordani; S Berent; K A Frey; N L Foster; D E Kuhl
Journal:  Ann Neurol       Date:  1997-07       Impact factor: 10.422

5.  Four subgroups of Alzheimer's disease based on patterns of atrophy using VBM and a unique pattern for early onset disease.

Authors:  Akihiko Shiino; Toshiyuki Watanabe; Kengo Maeda; Emi Kotani; Ichiro Akiguchi; Masayuki Matsuda
Journal:  Neuroimage       Date:  2006-08-10       Impact factor: 6.556

6.  Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia.

Authors:  P Pietrini; A Dani; M L Furey; G E Alexander; U Freo; C L Grady; M J Mentis; D Mangot; E W Simon; B Horwitz; J V Haxby; M B Schapiro
Journal:  Am J Psychiatry       Date:  1997-08       Impact factor: 18.112

7.  Frequency of stages of Alzheimer-related lesions in different age categories.

Authors:  H Braak; E Braak
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

8.  Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease.

Authors:  Cheryl L Grady; Anthony R McIntosh; Sania Beig; Michelle L Keightley; Hana Burian; Sandra E Black
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

9.  Dynamics of gray matter loss in Alzheimer's disease.

Authors:  Paul M Thompson; Kiralee M Hayashi; Greig de Zubicaray; Andrew L Janke; Stephen E Rose; James Semple; David Herman; Michael S Hong; Stephanie S Dittmer; David M Doddrell; Arthur W Toga
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

Review 10.  Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention.

Authors:  E Head; I T Lott; D Patterson; E Doran; R J Haier
Journal:  J Alzheimers Dis       Date:  2007-03       Impact factor: 4.472

View more
  29 in total

1.  Reduced caudate nuclei volumes in patients with congenital central hypoventilation syndrome.

Authors:  R Kumar; R Ahdout; P M Macey; M A Woo; C Avedissian; P M Thompson; R M Harper
Journal:  Neuroscience       Date:  2009-07-24       Impact factor: 3.590

2.  Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia.

Authors:  Marwan N Sabbagh; Kewei Chen; Joseph Rogers; Adam S Fleisher; Carolyn Liebsack; Dan Bandy; Christine Belden; Hillary Protas; Pradeep Thiyyagura; Xiaofen Liu; Auttawut Roontiva; Ji Luo; Sandra Jacobson; Michael Malek-Ahmadi; Jessica Powell; Eric M Reiman
Journal:  Alzheimers Dement       Date:  2015-04-04       Impact factor: 21.566

3.  Shape of the basal ganglia in preadolescent children is associated with cognitive performance.

Authors:  Curt A Sandman; Kevin Head; L Tugan Muftuler; Lydia Su; Claudia Buss; Elysia Poggi Davis
Journal:  Neuroimage       Date:  2014-05-17       Impact factor: 6.556

4.  Cognitive impairment and EEG background activity in adults with Down's syndrome: a topographic study.

Authors:  Svetla Velikova; Giuseppe Magnani; Claudia Arcari; Monica Falautano; Massimo Franceschi; Giancarlo Comi; Letizia Leocani
Journal:  Hum Brain Mapp       Date:  2011-05       Impact factor: 5.038

5.  Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.

Authors:  Eric Doran; David Keator; Elizabeth Head; Michael J Phelan; Ron Kim; Minodora Totoiu; Jorge R Barrio; Gary W Small; Steven G Potkin; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

7.  Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease.

Authors:  Marwan N Sabbagh; Adam Fleisher; Kewei Chen; Joseph Rogers; Camryn Berk; Eric Reiman; Michael Pontecorvo; Mark Mintun; Daniel Skovronsky; Sandra A Jacobson; Lucia I Sue; Carolyn Liebsack; Albert S Charney; Lauren Cole; Christine Belden; Thomas G Beach
Journal:  Arch Neurol       Date:  2011-11

8.  Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.

Authors:  Elizabeth Head; Eric Doran; Mihaela Nistor; MaryAnn Hill; Frederick A Schmitt; Richard J Haier; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

9.  Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.

Authors:  M S Rafii; S Zaman; B L Handen
Journal:  J Prev Alzheimers Dis       Date:  2021

10.  Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome?

Authors:  Troy T Rohn; Katie L McCarty; Julia E Love; Elizabeth Head
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2014-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.